Alligator Bioscience AB Interim Report January-June 2018

STOCKHOLM, July 12, 2018 /PRNewswire/ -- Positive data for our preclinical projects

Significant events April-June
• The ADC-1013 clinical phase I study performed by Janssen is ongoing with more than 80 patients recruited and the technology transfer to Biogen Inc. for the production of clinical material has been completed.

Preclinical data presented at scientific conferences:
• ATOR-1015 localizes to the tumor and selectively activates the immune system in the tumor, confirming the intended mechanism of action.
• ATOR-1017 potently activates T cells and NK cells, both important for immune-mediated tumor cell killing. The results confirm a best-in-class profile.
• ALG.APV-527 has the potential to selectively activate and enhance the T cell response in the tumor without activation of the immune system in the rest of the body.

Financial summary
April-June
• Net Sales, SEK 0.4 million (1.3).
• Operating result, SEK -39.1 million (-29.5).
• Result for the period, SEK -37.6 million (-31.0).
• Result per share, SEK -0.53 (-0.43).
• Cash, cash equivalents and bonds, SEK 518 million (547).
• Cash flow for the period SEK -31.1 million (-97.2)
January-June
• Net Sales, SEK 1.2 million (3.8).
• Operating result, SEK -83.1 million (-48.6).
• Result for the period, SEK -79.8 million (-50.5).
• Result per share, SEK -1.12 (-0.71).
• Cash flow for the period SEK -30.3 million (-116.1)

Financial summary (Group)

 



                               2018            2017            2018             2017

                                                                                                2017



                    Apr-Jun         Apr-Jun         Jan-Jun         Jan-Jun

                                                                                    Jan-Dec



    Net sales, TSEK
     (SEK thousand)             392           1,283           1,167            3,806

                                                                                              56,875



    Operating
     profit/loss            -39,108         -29,452         -83,102          -48,573

                                                                                             -62,299



    Profit/loss
     for the
     period, TSEK           -37,611         -31,000         -79,819          -50,502

                                                                                             -63,758



    Cash flow for
     the period,
     TSEK                   -31,072         -97,221         -30,299         -116,070

                                                                                            -183,173



    Cash, cash
     equivalents
     and bonds,
     TSEK                   518,393         615,024         518,393          615,024

                                                                                             547,041



    Equity ratio, %           95%            97%            95%             97%

                                                                                                 96%



    R&D costs as %
     of operating
     costs
     excluding
     impairments              72.5%          71.0%          75.9%           69.6%

                                                                                               73.3%



    Earnings per
     share before
     dilution, SEK            -0.53           -0.43           -1.12            -0.71

                                                                                               -0.89



    Earnings per
     share after
     dilution, SEK            -0.53           -0.43           -1.12            -0.71

                                                                                               -0.89



    Average number
     of employees                49              41              50               39                 42

 

Read the complete report in the attached pdf.

For further information, please contact:
Per Norlén, CEO, per.norlen@alligatorbioscience.com, +46-46-286-42-80
Per-Olof Schrewelius, CFO, per-olof.schrewelius@alligatorbioscience.com, +46-46-286-42-85
Cecilia Hofvander, Director IR & Communications, cecilia.hofvander@alligatorbioscience.com, +46-46-286-44-95

Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden.
Phone +46-46-286-42-80
www.alligatorbioscience.com

This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 8:00 a.m. CET on July 12, 2018.

About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab-interim-report-january-june-2018,c2573835

The following files are available for download:

    http://mb.cision.com/Main/12681/2573835/877166.pdf Alligator Bioscience AB
                                                       Interim Report January-
                                                       June 2018

View original content:http://www.prnewswire.com/news-releases/alligator-bioscience-ab-interim-report-january-june-2018-300679958.html

SOURCE Alligator Bioscience

 

Back to news